Premium
Inhibition of Vascular Endothelial Growth Factor by Macrolides in Cultured Fibroblasts from Nasal Polyps
Author(s) -
Matsune Shoji,
Sun Dong,
Ohori Junichiro,
Nishimoto Kengo,
Fukuiwa Tatsuya,
Ushikai Masato,
Kurono Yuichi
Publication year - 2005
Publication title -
the laryngoscope
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.181
H-Index - 148
eISSN - 1531-4995
pISSN - 0023-852X
DOI - 10.1097/01.mlg.0000177031.06112.50
Subject(s) - vascular endothelial growth factor , nasal polyps , clarithromycin , tumor necrosis factor alpha , hypoxia (environmental) , medicine , chronic sinusitis , vascular endothelial growth inhibitor , pharmacology , immunology , vascular endothelial growth factor a , sinusitis , cancer research , chemistry , vegf receptors , organic chemistry , oxygen , helicobacter pylori
Abstract Objective: In order to study a new mechanism of efficacy of 14‐membered ring macrolides in treating chronic rhinosinusitis, inhibitory effects of macrolides on vascular endothelial growth factor production were examined in vitro. Methods: Vascular endothelisal growth factor production in cultured fibloblasts from human nasal polyps obtained from surgery for chronic paranasal sinusitis stimulated by hypoxia or tumor necrosis factor‐α was assessed under the administration of Clarithromycin or Roxisthromycin by enzyme linked immunosorbent assay and reverse transcriptase polymerase chain‐reaction. Results: Dose‐dependent inhibitory effects on vascular endothelisal growth factor production stimulated by hypoxia or tumor necrosis factor‐α were noted in the groups treated with Clarithromycin and Roxisthromycin, including inhibition of vascular endothelisal growth factor mRNA levels. Conclusion: While, to date, several evidences have indicated that the mechanisms by which 14‐membered ring macrolides reduce inflammation are not simply bactericidal, these results suggest another new mechanism of efficacy of macrolides in treating chronic rhinosinusitis.